Posted on 03/23/2022 2:56:36 PM PDT by ConservativeMind
In trials of ivermectin as a treatment for COVID-19, the relative risk of mortality varies with strongyloidiasis prevalence, according to research published online March 21 in JAMA Network Open.
Avi Bitterman, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the association between regional prevalence of strongyloidiasis and ivermectin trial results for the outcome of mortality in a meta-analysis of randomized clinical trials using ivermectin as a treatment for COVID-19. Data were included from 12 trials, with 3,901 patients: four and eight trials took place in regions of high and low strongyloidiasis prevalence, respectively.
The researchers found that there was no significantly decreased risk of mortality in ivermectin trials that took place in areas of low regional strongyloidiasis prevalence (relative risk, 0.84; 95 percent confidence interval, 0.60 to 1.18; P = 0.31). In contrast, a significantly decreased risk of mortality was seen in ivermectin trials that took place in areas of high regional strongyloidiasis prevalence (relative risk, 0.25; 95 percent confidence interval, 0.09 to 0.70; P = 0.008). The difference between the results of groups with low and high strongyloidiasis prevalence was significant. For each 5 percent increase in strongyloidiasis prevalence, meta-regression analysis revealed a decrease of 38.83 percent in relative risk.
"Results of ivermectin trials in strongyloidiasis-endemic regions may not extrapolate to strongyloidiasis-nonendemic regions," the authors write. "Future trials in nonendemic regions may provide insight into the true effect of ivermectin in this context. In the interim, we strongly caution against extrapolation for patients not at increased risk for strongyloidiasis."
(Excerpt) Read more at medicalxpress.com ...
Interesting.
Bkmi
I have heard people saying this for over a year, that ivermectin can clear parasite infections that suppress the immune system. Effectively, it cures a comorbidity, not COVID itself.
ConservativeMind wrote: “It’s not clear why from the write up, but it seems to me that either Ivermectin abolished both infections, saving those more likely to die,...”
Or perhaps the ivermectin suppressed the worms resulting in a better health perspective. IOW, ivermectin didn’t do a thing for the COVID but it did kill off the worms. This would be consistent with those without a worm infection showing no improvement.
Having posted previously on links found between parasite infestation, particularly ascaris and roundworm and asthma, and also parasite infestation and cancer, particularly colon cancer, this makes sense.
Researcher Hulda Clark found the above and wrote six books on the subject, healing from these.
https://www.valleyvet.com/ct_detail.html?pgguid=4D9A49D8-394F-46B3-883C-733D88C2C257
Bkmk
Jeffers has some for $6.99.
Interesting, indeed. Is it possible that people in areas with high prevalence of strongyloidiasis have been on ivermectin for many years? Perhaps it is the amount of time you’ve been on ivermectin that created high serum levels as opposed to people who took it only when they got sick and didn’t have the same serum levels.
Actually, they are still saying it is unavailable.
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
How about the other factors, such as clinical trials in low prevalence regions having been those designed to fail (e.g., with low dosage)?
Just like the HCQ trial scams, I bet.
I must have hit them at the right time. They show unavailable now.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.